NEUROCRINE BIOSCIENCES ($NBIX) posted quarterly earnings results for Q3 2026 on Monday, November 2nd. The company reported earnings of $3.29 per share, beating estimates of $1.95 by $1.34. The company also reported revenue of $1,122,700,000, beating estimates of $1,063,896,934 by $58,803,066.
Stock price change since market close: +6.89%
You can see Quiver Quantitative's $NBIX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
NEUROCRINE BIOSCIENCES Insider Trading Activity
NEUROCRINE BIOSCIENCES insiders have traded $NBIX stock on the open market 30 times in the past 6 months. Of those trades, 0 have been purchases and 30 have been sales.
Here’s a breakdown of recent trading of $NBIX stock by insiders over the last 6 months:
- KEVIN CHARLES GORMAN sold 245,088 shares for an estimated $37,824,872
- JULIE COOKE (Chief Human Resources Officer) has made 0 purchases and 5 sales selling 36,937 shares for an estimated $5,770,235.
- STEPHEN A SHERWIN has made 0 purchases and 5 sales selling 25,000 shares for an estimated $4,132,968.
- INGRID DELAET (Chief Regulatory Officer) has made 0 purchases and 5 sales selling 21,199 shares for an estimated $3,747,947.
- DARIN LIPPOLDT (Chief Legal Officer) has made 0 purchases and 4 sales selling 20,000 shares for an estimated $3,497,506.
- JUDE ONYIA (Chief Scientific Officer) has made 0 purchases and 2 sales selling 22,000 shares for an estimated $3,473,575.
- RICHARD F POPS sold 15,000 shares for an estimated $2,364,760
- LESLIE V NORWALK has made 0 purchases and 3 sales selling 6,310 shares for an estimated $1,028,180.
- DAVID W. BOYER (Chief Corp. Affairs Officer) has made 0 purchases and 2 sales selling 4,714 shares for an estimated $739,073.
- MATT ABERNETHY (Chief Financial Officer) sold 2,311 shares for an estimated $363,284
- ERIC BENEVICH (Chief Commercial Officer) sold 2,154 shares for an estimated $333,029
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
NEUROCRINE BIOSCIENCES Hedge Fund Activity
We have seen 429 institutional investors add shares of NEUROCRINE BIOSCIENCES stock to their portfolio, and 321 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 6,398,674 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,078,400,522
- WELLINGTON MANAGEMENT GROUP LLP removed 1,354,898 shares (-97.5%) from their portfolio in Q2 2026, for an estimated $228,347,734
- MILLENNIUM MANAGEMENT LLC removed 1,235,862 shares (-99.1%) from their portfolio in Q2 2026, for an estimated $208,286,002
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 1,184,345 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $199,603,584
- AQR CAPITAL MANAGEMENT LLC removed 1,120,930 shares (-22.7%) from their portfolio in Q2 2026, for an estimated $188,915,937
- LOS ANGELES CAPITAL MANAGEMENT LLC removed 1,087,730 shares (-84.2%) from their portfolio in Q2 2026, for an estimated $183,320,575
- TWO SIGMA INVESTMENTS, LP removed 984,310 shares (-32.2%) from their portfolio in Q2 2026, for an estimated $165,890,685
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
NEUROCRINE BIOSCIENCES Price Targets
Multiple analysts have issued price targets for $NBIX recently. We have seen 5 analysts offer price targets for $NBIX in the last 6 months, with a median target of $195.0.
Here are some recent targets:
- Brian Abrahams from RBC Capital set a target price of $195.0 on 07/07/2026
- Corinne Johnson from Goldman Sachs set a target price of $213.0 on 06/02/2026
- Jeffrey Walch from Bernstein set a target price of $221.0 on 05/22/2026
- Anupam Rama from JP Morgan set a target price of $185.0 on 05/08/2026
- Danielle Brill from Truist Securities set a target price of $155.0 on 05/07/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
